In our in vitro and in vivo studies, FPFT-2216 enhanced p53 stabilization and the tumor growth-inhibitory activities of MDM2 inhibitors against hematopoietic malignant cell lines, including AML. Here, TP53 is linked to acute myeloid leukemia.